Table 1.

Previous studies describing the impact of CP therapy.

Sr. no	Title of the study	Year	Indication	No. of participants	Outcomes	References
1.	Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients	2003	SARS	19 SARS patients (retrospective non-randomized study)	Short hospital stays and low mortality was observed in CP treated patients. CP therapy showed no adverse effects following treatment	[6]
2.	Use of convalescent plasma therapy in SARS patients in Hong Kong	2003	SARS	80	Early discharge rate from hospital was observed in CP treated patients	[3]
3.	Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection	2009–10	Severe influenza A virus (H1N1 2009)	93 HIN1 patients (prospective cohort study)	Viral load and cytokine response was reduced after the CP transfusion. Also the mortality rate was significantly lower in the CP transfusion group than the control group.	[2]
4.	Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets	2015–16	MERS	Common marmoset MERS-CoV infection model-3 groups	Common Marmosets treated with mAb and CP therapy, both the groups showed reduction in the clinical symptoms.	[8]
5.	Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone.	2014–15	Ebola	69 patients	Increased recovery and clinical symptoms in CP treated group	[9]
6.	The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States	2014	Ebola	2 (case reports)	Both patients recovered. One patient underwent multi-organ failure	[10]
7.	Effectiveness of convalescent plasma therapy in severe COVID-19 patients	2020	COVID-19	10 severe COVID-19 patients	Viral load decreased in the treatment group along with improvement in the clinical symptoms. Also lymphocyte count increased with reduction in CRP. Overall CP therapy showed promising results with no side effects.	[11]
8.	Treatment of 5 critically ill patients with COVID-19 with convalescent plasma	2020	COVID-19	5 critically ill COVID-19 patients (case series)	Body temperature normalized, SOFA (Sequential Organ Failure Assessment: with higher score indicating more illness) score decreased and Pao₂/Fio₂increased. Also viral load decreased and became negative within 12 days of CO transfusion.	[12]
9.	Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea	2020	COVID-19	2 COVID-19 patients with multiple diseases (case reports)	After CP therapy fever subsided, and oxygen demand decreased in both the cases. CRP and IL-6 levels decreased to normal range. Both the patients showed a favorable outcome after the use of CP therapy in addition to systemic corticosteroid treatment.	[13]